CD7CAR T cells

CD7CAR T cells are a type of chimeric antigen receptor (CAR) T-cell therapy designed to target CD7, a protein highly expressed on T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) cells. The specific variant discussed in the provided context, NS7CAR (naturally selected CD7CAR), is manufactured without additional genetic manipulations to ablate the CD7 gene or block CD7 cell surface expression. Instead, it utilizes a novel approach where the CD7 molecules on the NS7CAR T cells are masked or sequestered by the CD7-targeting CAR, minimizing fratricide (self-killing of CAR T cells). The CAR construct typically includes a CD7-specific single-chain variable fragment (scFv) derived from the TH69 monoclonal antibody, fused to co-stimulatory domains like CD28, 4-1BB, and CD3ζ. This therapy aims to induce T-cell activation and cytotoxicity against CD7-positive malignant cells. It has shown promising safety and efficacy in patients with relapsed/refractory T-ALL/LBL and other CD7-positive hematologic malignancies.

Other names

NS7CAR T cellsNS-7CAR T cellsNS 7CAR T cellsanti-CD7 CAR T cellsanti-CD-7 CAR T cellsanti-CD 7 CAR T cells